NanoViricides

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.

Our mission is to create nanosized medicines that can target and destroy viruses, and bring relief to humanity by tackling global viral diseases.

Our vision is to create a world where humanity is free from global viruses and their consequences, and where healthcare and relief are universally accessible.

NanoViricides has been awarded numerous awards, such as the Technology Award from European Biotech Summit in 2011, the Drug Discovery Award from Euroinvent in 2016, and the Breakthrough Technology Award from the Wall Street Journal Pro Biotech Summit in 2017.